← Back to Search

Regional Anesthesia

Nerve Block for Rib Fractures

N/A
Recruiting
Led By Daniel Kreider, MD
Research Sponsored by WellSpan Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of randomization until the date of discharge from the hospital or death from any cause, whichever came first, assessed up to 100 months
Awards & highlights
No Placebo-Only Group

Summary

This trial studies the effect of a nerve block to reduce pain in patients with multiple rib fractures, compared to using pain relief medicines alone.

Who is the study for?
This trial is for adults over 18 with one or more rib fractures confirmed by X-ray or CT scan, who visit WellSpan York Hospital's ED and need IV painkillers or oral opioids. It excludes those under 18, unable to consent, allergic to local anesthesia, needing urgent surgery, discharged immediately, revisiting for the same injury, or with other major injuries.
What is being tested?
The study compares a pain relief technique called Serratus Anterior Plane Block (SAPB) guided by ultrasound against standard pain medications in patients with multiple rib fractures. The focus is on pain management effectiveness and overall patient outcomes like medication use and hospital stay length.
What are the potential side effects?
While not explicitly listed here, side effects of SAPB may include discomfort at injection site, infection risk from needle insertion and potential nerve damage. Standard analgesics can cause drowsiness, constipation, nausea and increased risk of dependency.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of randomization until the date of discharge from the hospital or death from any cause, whichever came first, assessed up to 100 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of randomization until the date of discharge from the hospital or death from any cause, whichever came first, assessed up to 100 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual Analog Pain Score (VAS) at 2 hours
Secondary study objectives
Length of Stay (hours)
Morphine Milligrams Equivalent (MME)
Pain Score
+3 more
Other study objectives
Safety Outcomes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Serratus Anterior Plane BlockExperimental Treatment2 Interventions
Subjects will undergo serratus anterior plane block, in addition to standard of care analgesic medications at the discretion of the treatment team.
Group II: Standard Analgesic MedicationsActive Control1 Intervention
Subjects will receive standard of care analgesic medications at the discretion of the treatment team.

Find a Location

Who is running the clinical trial?

WellSpan HealthLead Sponsor
30 Previous Clinical Trials
2,004,800 Total Patients Enrolled
Daniel Kreider, MDPrincipal InvestigatorWellSpan Health

Media Library

Serratus Anterior Plane Block (SAPB) (Regional Anesthesia) Clinical Trial Eligibility Overview. Trial Name: NCT05748366 — N/A
Multiple Rib Fractures Research Study Groups: Serratus Anterior Plane Block, Standard Analgesic Medications
Multiple Rib Fractures Clinical Trial 2023: Serratus Anterior Plane Block (SAPB) Highlights & Side Effects. Trial Name: NCT05748366 — N/A
Serratus Anterior Plane Block (SAPB) (Regional Anesthesia) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05748366 — N/A
~5 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top